A new trading day began on Friday, with Immunome Inc (NASDAQ: IMNM) stock price up 8.57% from the previous day of trading, before settling in for the closing price of $14.71. IMNM’s price has ranged from $6.65 to $30.96 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 26.26%. With a float of $49.02 million, this company’s outstanding shares have now reached $60.05 million.
Let’s determine the extent of company efficiency that accounts for 55 employees. In terms of profitability, gross margin is 87.4%, operating margin of -2518.49%, and the pretax margin is -2435.02%.
Immunome Inc (IMNM) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immunome Inc is 18.38%, while institutional ownership is 79.08%. The most recent insider transaction that took place on Aug 16 ’24, was worth 97,608. In this transaction Director of this company bought 7,000 shares at a rate of $13.94, taking the stock ownership to the 16,615 shares. Before that another transaction happened on Aug 15 ’24, when Company’s Chief Scientific Officer sold 3,524 for $13.93, making the entire transaction worth $49,072. This insider now owns 16,000 shares in total.
Immunome Inc (IMNM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 26.26% per share during the next fiscal year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Here are Immunome Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 88.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.69, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach -2.82 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Looking closely at Immunome Inc (NASDAQ: IMNM), its last 5-days average volume was 0.46 million, which is a drop from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 65.15%. Additionally, its Average True Range was 0.97.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 85.37%, which indicates a significant decrease from 86.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.41% in the past 14 days, which was higher than the 66.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.20, while its 200-day Moving Average is $15.80. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $16.38. Second resistance stands at $16.78. The third major resistance level sits at $17.50. If the price goes on to break the first support level at $15.26, it is likely to go to the next support level at $14.54. Should the price break the second support level, the third support level stands at $14.14.
Immunome Inc (NASDAQ: IMNM) Key Stats
With a market capitalization of 959.00 million, the company has a total of 59,969K Shares Outstanding. Currently, annual sales are 14,020 K while annual income is -106,810 K. The company’s previous quarter sales were 2,360 K while its latest quarter income was -36,120 K.
